Reasons for exclusion from thrombolytic therapy following acute ischemic stroke

被引：121

作者：

Cocho, D

Belvís, R

Martí-Fàbregas, J

Molina-Porcel, L

Díaz-Manera, J

Aleu, A

Pagonabarraga, J

García-Bargo, D

Mauri, A

Martí-Vilalta, JL

机构：

[1] Univ Autonoma Barcelona, Serv Neurol, Hosp Santa Cruz & San Pablo, Dept Neurol,Cerebrovasc Unit, E-08025 Barcelona, Spain

[2] Univ Autonoma Barcelona, Dept Emergency, Hosp Santa Cruz & San Pablo, E-08025 Barcelona, Spain

来源：

NEUROLOGY | 2005年 / 64卷 / 04期

关键词：

D O I：

10.1212/01.WNL.0000152041.20486.2F

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors' center.

引用

页码：719 / 720

页数：2

共 9 条

[1] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility [J].

Barber, PA ;

Zhang, J ;

Demchuk, AM ;

Hill, MD ;

Buchan, AM .

NEUROLOGY, 2001, 56 (08) :1015-1020

[2] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].

Hacke, W ;

Kaste, M ;

Fieschi, C ;

von Kummer, R ;

Davalos, A ;

Meier, D ;

Larrue, V ;

Bluhmki, E ;

Davis, S ;

Donnan, G ;

Schneider, D ;

Diez-Tejedor, E ;

Trouillas, P .

LANCET, 1998, 352 (9136) :1245-1251

[3] Use of tissue-type plasminogen activator for acute ischemic stroke - The Cleveland area experience [J].

Katzan, IL ;

Furlan, AJ ;

Lloyd, LE ;

Frank, JI ;

Harper, DL ;

Hinchey, JA ;

Hammel, JP ;

Qu, A ;

Sila, CA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1151-1158

[4] Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience [J].

Koennecke, HC ;

Nohr, R ;

Leistner, S ;

Marx, P .

STROKE, 2001, 32 (05) :1074-1078

[5] TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].

MARLER, JR ;

BROTT, T ;

BRODERICK, J ;

KOTHARI, R ;

ODONOGHUE, M ;

BARSAN, W ;

TOMSICK, T ;

SPILKER, J ;

MILLER, R ;

SAUERBECK, L ;

JARRELL, J ;

KELLY, J ;

PERKINS, T ;

MCDONALD, T ;

RORICK, M ;

HICKEY, C ;

ARMITAGE, J ;

PERRY, C ;

THALINGER, K ;

RHUDE, R ;

SCHILL, J ;

BECKER, PS ;

HEATH, RS ;

ADAMS, D ;

REED, R ;

KLEI, M ;

HUGHES, S ;

ANTHONY, J ;

BAUDENDISTEL, D ;

ZADICOFF, C ;

RYMER, M ;

BETTINGER, I ;

LAUBINGER, P ;

SCHMERLER, M ;

MEIROSE, G ;

LYDEN, P ;

RAPP, K ;

BABCOCK, T ;

DAUM, P ;

PERSONA, D ;

BRODY, M ;

JACKSON, C ;

LEWIS, S ;

LISS, J ;

MAHDAVI, Z ;

ROTHROCK, J ;

TOM, T ;

ZWEIFLER, R ;

DUNFORD, J ;

ZIVIN, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587

[6] Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment [J].

O'Connor, RE ;

McGraw, P ;

Edelsohn, L .

ANNALS OF EMERGENCY MEDICINE, 1999, 33 (01) :9-14

[7]

Rey A, 1995, Rev Neurol, V23, P272

[8] Delayed hospital arrival for acute stroke: The Minnesota stroke survey [J].

Smith, MA ;

Doliszny, KM ;

Shahar, E ;

McGovern, PG ;

Arnett, DK ;

Luepker, RV .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (03) :190-+

[9] Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke [J].

Wardlaw, JM ;

Warlow, CP ;

Counsell, C .

LANCET, 1997, 350 (9078) :607-614

← 1 →